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A novel canine papillomavirus, CfPV-2, was cloned from a footpad lesion of a golden retriever. Unlike the known canine oral papillomavirus
(COPV), which has a double-stranded DNA genome size of 8607 bps, the genome of CfPV-2 is 8101 bps. Some of this size difference is due to an
abbreviated early-late region (ELR), which is 1200 bps shorter than that of COPV. However, CfPV-2 has other differences from COPV, including
the presence of an E5 ORF between the E2 gene and the ELR and an enlarged E4 ORF (one of the largest PV E4 open reading frames). The
genome of CfPV-2 shares low homology with all the other papillomaviruses and, even in the most highly conserved ORF of L1, the nucleotide
sequence shares only 57% homology with COPV. Due to this highly divergent DNA sequence, CfPV-2 establishes a new PV genus, with its
closest phylogenetic relatives being amongst the Xi and Gamma genuses. CfPV-2 also has unique biological features; it induces papillomas on
footpads and interdigital regions which, if infection is persistent, can progress to highly metastatic squamous cell carcinoma. CfPV-2 does not
induce oral papillomas in immunocompetent animals and antibodies generated against COPV and CfPV-2 are type-specific. The availability of a
new canine papillomavirus with differing genetic and biological properties now makes it possible to study type-specific host immune responses,
tissue tropism and the comparative analysis of viral gene functions in the dog.
© 2006 Elsevier Inc. All rights reserved.Keywords: Papillomavirus; COPV; CfPV-2Introduction
Papillomaviruses are small, non-enveloped, double-stranded
DNAviruses that induce hyperproliferative lesions of cutaneous
and mucosal epithelia. In humans, more than 100 different
human papillomaviruses (HPVs) have been isolated and cloned
(zur Hausen, 2002). A subset of HPVs, the high-risk types, is
associated with the development of malignancy, most fre-
quently with cervical cancer. Approximately 99% of human
cervical cancers contain HPV DNA of the high-risk types
(Walboomers et al., 1999). Papillomaviruses are also found in⁎ Corresponding author. Fax: +1 202 687 2933.
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doi:10.1016/j.virol.2006.08.029many other vertebrate species and have been used as
experimental models for analyzing virus–host interactions,
including humoral and cellular immune responses to virus
infection. Indeed, the canine oral papillomavirus (COPV) has
been used as a prototype mucosal papillomavirus for develop-
ing a vaccine based upon the viral L1 capsid protein. Studies
with COPV (Suzich et al., 1995) provided the pre-clinical
foundation for the current development of a human papilloma-
virus vaccine (Harper et al., 2004).
Canine oral papillomavirus (COPV) was first isolated and
sequenced from oral papillomas in dogs in 1994 (Delius et al.,
1994). Canine oral papillomatosis is a contagious disease of
young dogs and papillomas usually appear 3–4 weeks after
infection and last for about 4 weeks before spontaneous
regression. COPV infection can be prevented by immunization
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1995), GST-L1 protein (Yuan et al., 2001) or L1 DNA vaccines
(Stanley et al., 2001).
Recently, we became aware of several dogs with chronic
papillomas of the footpad that exhibited histologic features
characteristic of papillomavirus infection. In some cases, the
dogs had been vaccinated against COPV, suggesting that
another type of canine papillomavirus might be the etiologic
agent. These footpad lesions were also much more persistent
than COPV lesions, in some cases lasting more than 6 months.
Usually the footpad lesions were associated with a clinical
history of immunosuppression or with a stressful environmental
setting. To determine whether there was a new canine
papillomavirus associated with this disease, we cloned,
sequenced and characterized the viral DNA from a footpad
papilloma of a Golden retriever that had been in intensive
training as a guide dog for the blind. Our results verify the
existence of a new and divergent canine papillomavirus. We
have designated this new virus as Canis familiaris papilloma
virus type 2 (CfPV-2).
Results
Histology and immunohistochemistry of a canine footpad
lesion
The food pad lesion of a golden retriever was biopsied, fixed
in formalin and embedded in paraffin using standard histolo-
gical techniques. Slides of these paraffin-embedded biopsies
were then stained and examined microscopically (Fig. 1A, 10×
and 40×). The tumor was determined to be an inverted or
endophytic papilloma, differing from the normal exophytic
papillomas induced by COPV. To determine if this papilloma
were induced by papillomavirus, we stained additional sections
of the tumor with DAKO papillomavirus L1 antibody (Fig. 1B,
10× and 40×), which was generated against denatured
papillomavirus L1 protein and reacts with most papillomavirus
isolates (regardless of species origin). The immunohisto-
chemistry slides of the tumor showed positive staining for
papillomavirus L1 protein within the nuclei of the differentiated
keratinocytes. The strong staining with this antibody (specifi-
cally within the differentiated layers of the epidermis where the
L1 protein is synthesized) confirmed that the lesion contained
and expressed a papillomavirus.
To further substantiate the presence of papillomavirus, we
extracted the footpad tumors and attempted to isolate viral
particles as described in Materials and methods. When
preparations were examined by electron microscopy, we
observed abundant non-enveloped, 55 nm diameter virions
which were very similar to COPV and characteristic of
papillomaviruses in general (Fig. 1C). Finally, to determine if
this viral isolate might be different than COPV, we examined the
reactivity of isolated virions of COPVand the new isolate with a
monoclonal anti-AU1 antibody. This monoclonal antibody
recognizes the COPV L1 amino acid sequence, DTYRYI. As
shown in the Western blot experiments in Fig. 1D, the reactivity
of the new viral isolate with anti-AU1 antibody was signifi-cantly weaker than with COPV virions, suggesting that a
different type of canine papillomavirus might be present.
Complete DNA sequence of the CfPV-2 genome
Viral genomic DNAwas purified from either food pads warts
or purified virions propagated in a xenograft system and
sequenced as described in Materials and methods. The complete
nucleotide sequence (GenBank accession number AY722648)
of this virus consists of 8101 base pairs (bps) and has a GC-
content of 45%. The size is substantially smaller than that of
COPV (8607 bps) which has the largest genome among
papillomaviruses (Delius et al., 1994). We named this new
virus, CfPV-2 (Canis familiaris papillomavirus type 2).
Phylogenetic analysis
The L1 ORF is the most conserved gene with the
papillomavirus genome and has been used for the classification
of papillomaviruses (de Villiers et al., 2004). In order to make an
optimal phylogenetic analysis, L1 proteins from 29HPVs and 17
animal papillomaviruses were selected according to their genus
(de Villiers et al., 2004), and aligned using Clustal W
(Thompson et al., 1994) with MEGA version 3.0 (Kumar and
Nei, 2004). Based on the alignment, a phyllogenetic tree (Fig. 2)
was assembled by using the neighbor joining method with
MEGA version 3.0 (Kumar and Nei, 2004). CfPV-2 was most
closely related to the genus xi-papillomaviruses (BPV3, 4 and 6)
and genus gamma-papillomaviruses (HPV4, 48, 50 and 60) and
only distantly related to the genus lambda-papillomaviruses
(COPV and Felis domesticus papillomavirus).
Open reading frames of viral genes
Similar to COPVand all other papillomaviruses, CfPV-2 has
all of its open reading frames (ORFs) on the same coding strand
of its circular double-stranded DNA genome. A diagram
comparing the ORFs of CfPV-2 and COPV is shown in Fig. 3.
CfPV-2 has eight ORFs that encode six early (E) proteins: E1,
E2, E4, E5, E6 and E7. In addition there are two late (L) proteins:
L1 and L2. The location of the ORFs and the predicted size of the
encoded viral proteins are compared with the corresponding
ones from COPV in Table 1.
Comparison of CfPV-2 ORFs to those of related
papillomaviruses
Based upon the preceding phyllogenetic analysis and ORF
identification of CfPV-2, we compared its ORFs to those of
related papillomaviruses. Comparisons were made with COPV
(which infects the same host), BPV-1 (which is another animal
papillomavirus encoding a small E5 protein), HPV-16 (which is
an E5-containing human papillomavirus), BPV-6 (a xi-papillo-
mavirus, a closely related animal paillomavirus) and HPV-4 (a
gamma-papillomavirus, a closely related human papilloma-
virus). Comparisons were investigated by the pairwise align-
ment of corresponding ORFs nucleotides and proteins, as
Fig. 1. Canine footpad tumors contain and express a papillomavirus. (A, 10× and 40×) Histology of footpad tumors. The foot lesions, which were biopsied and
examined histologically, showed the microscopic appearance of benign squamous cell papillomas. The tumors were inward-growing (endophytic) and the squamous
epithelial cells showed evidence of cytoplasmic and nuclear vacuolation in the more differentiated layers of the epidermis, consistent with a papillomavirus infection.
(B) The differentiated squamous cells of the tumor express intranuclear papillomavirus L1 protein. Immunohistochemistry demonstrated that the nuclei of the
differentiated cells reacted specifically with DAKO anti-papillomavirus capsid antibody (brown staining of nuclei), indicating the expression of papillomavirus L1
capsid protein and suggesting viral replication. (C). Footpad tumors contain papillomavirus virions. The footpad lesions were extracted as described and virus was
purified, negatively stained, and examined by electron microscopy. Virions were observed that exhibited the size (55 nm diameter) and structure of papillomavirus. (D)
COPVand the new viral isolate (CfPV-2) show different reactivity with an L1 monoclonal antibody. The indicated amounts of viral protein from purified COPVand
CfPV-2 were separated by SDS-PAGE and immunoblotted with the AU1 anti-L1 monoclonal antibody. The new viral isolate showed reduced reactivity compared to
COPV, suggesting the presence of a unique papillomavirus type.
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Wunsch, 1970) of Emboss Pairwise Alignment Algorithms
(http://www.ebi.ac.uk/emboss/align/). Low identity of nucleo-
tide sequences (<60%) and in amino acid sequences (<72%)
were observed (Table 2) with all the papillomaviruses analyzed.
The difference between the CfPV-2 and COPV genome size
and organization was striking. The size of CfPV-2 genome(8101 bps) was much smaller than that of COPV (8607) and is
more similar in size to most papillomaviruses. CfPV-2 has an
early-late-region (ELR) of 368 bps, which is approximately
1200 bps shorter than that of COPV (which has the longest ELR
sequence of any papillomavirus). In contrast to COPV, CfPV-2
contains an E5 ORF located between E2 and ELR. CfPV-2 also
has an enlarged E4 ORF, which is one of the longest E4
Fig. 3. Linear representation of the ORFs of the COPV and CfPV-2 genome. The open reading frames of the COPV and CfPV-2 virus genomes are represented
diagramatically.
Fig. 2. Phylogenetic analysis of the L1 sequences of CfPV-2 with those from 29 human papillomaviruses and 18 animal papillomaviruses. The L1 gene of CfPV-2 was
compared with a variety of divergent papillomaviruses in order to establish its closest relatives. The analyzed papillomavirus genomes included were FcPV (K02019),
bovine BPV-1 (NC_001522), BPV-2 (NC_001521), BPV-3 (NC_004197)BPV-4 (X05817), canine oral COPV (NC_001619), Canine papillomavirus type 2 CfPV-2
(AY722648), cotton rabbit CRPV (NC_001541), deer DPV (NC_001523), Equus caballus EcPV-1 (AF498323), European elk EEPV (NC_001524), Felis domesticus
FdPV-1 (AF480454), Hamster oral HaOPV (E15110), HPV-1 (NC_001356), HPV-3 (NC_001588), HPV-4 (NC_001457), HPV-5 (NC_001531), HPV-6b
(NC_000904), HPV-9 (NC_001596), HPV-10 (X74465), HPV-16 (NC_001526), HPV-18 (NC_001357), HPV-26 (X74472), HPV-29 (NC_001685), HPV-32
(X74475), HPV-34 (X74476), HPV-41 (X56147), HPV-42 (M73236), HPV-48 (NC_001690), HPV-49 (NC_001591), HPV-50 (NC_001691), HPV-53 (NC_001593),
HPV-54 (U37488), HPV-60 (NC_001693), HPV-61 (U31793), HPV-63 (X70828), HPV-90 (AY057438), HPV-92 (AF531420), HPV-94 (AJ620211), HPV-96
(AY382779), Mastomys natalensis MnPV (NC_001605), Ovine OvPV 1 (NC_001789), OvPV 2 (NC_001790), Psittacus erithacus PePV (AF502599), Phocoena
spinipinnis PsPV 1 (NC_003348), Rhesus RhPV 1 (NC_001678) and rabbit oral ROPV (NC_002232).
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Table 2
Percent nucleotide and amino acid identity of the CfPV-2 ORFs with those of
COPV, BPV-1, HPV-16, BPV-6 and HPV-4
CfPV-2 COPV BPV-1 HPV16 BPV-6 HPV-4
E6 48(37) 41(33) 47(40) N/A 47(48)
E7 50(40) 42(21) 47(46) 53(57) 55(59)
E1 58(63%) 53(53) 55(56) 56(31) 59(69)
E2 43(40) 34(25) 41(38) 47(44) 48(46)
E4 24(18) 24(15) 21(11) 37(28) 39(31)
E5 N/A 52(29) 36(27) N/A N/A
L2 49(49) 48(41) 45(44) 51(53) 53(52)
L1 57(66) 56(65) 55(62) 59(71) 58(70)
The nucleotide and amino acid identities of the indicated ORFs are represented
in parentheses.
Table 1
Nucleotide position of the ORFs of COPV and CfPV-2
ORF Virus Start ORF Stop codon Bases Amino acids
E6 COPV 102 536 435 144
CfPV-2 105 512 408 135
E7 COPV 533 826 294 97
CfPV-2 515 811 297 98
E1 COPV 816 2609 1794 597
CfPV-2 795 2618 1824 607
E2 COPV 2551 3708 1158 383
CfPV-2 2557 4152 1596 531
E4 COPV 3116 3461 345 115
CfPV-2 2912 3907 996 331
E5 COPV N/A N/A N/A N/A
CfPV-2 4169 4294 126 41
L2 COPV 5288 6829 1542 513
CfPV-2 4662 6188 1527 508
L1 COPV 6837 8348 1521 503
CfPV-2 6202 7713 1512 503
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highly conserved L1 ORF, the CfPV-2 nucleotide sequence only
shares 57% homology with that of COPV. According to the
papillomavirus classification system (de Villiers et al., 2004),
this defines CfPV-2 as a distinct papillomavirus genus (where
less than 60% homology defines a new genus).
The E6 proteins of both CfPV-2 and COPV contain four
C-X-X-C motifs. However, unlike COPV, the predicted CfPV-2
E6 protein also contains a carboxyl-terminal PDZ domain
protein binding motif (D-S-C-V-COOH). This suggests that
CfPV-2 E6 may behave like high-risk HPV-16 which can bind
to PDZ proteins and, in some cases, lead to their E6AP-
mediated ubiquitination and proteolysis (Lee et al., 2000;
Nakagawa and Huibregtse, 2000; Thomas et al., 2005).
The predicted E7 proteins of CfPV-2 and COPV have two
C-X-X-C motifs within their carboxyl terminal half. However,
the CfPV-2 E7 protein lacks an Rb binding site (L-X-C-X-E)
which is present in COPV E7. This implies that CfPV-2 E7 may
not able to bind and degrade the retinoblastoma tumor
suppressor protein. Interestingly, Narechania et al. (2004) have
observed that papillomaviruses that induce fibropapillomas
often have characteristic E5 and E7 proteins. Specifically, the E7
proteins of PVs that induce fibropapillomas lack an Rb binding
domain. However, despite lacking this Rb-binding domain in
E7, CfPV-2 does not induce fibropapillomas, suggesting that
there may be complex interactions between the E5 and E7
proteins for inducing the fibromatous component of tumors.
The CfPV-2 E1 protein shares the highest similarity with the
other papillomavirus early proteins. Like COPV E1, it contains
a cyclin interaction motif (the RXL motif) which mediates E1
interaction with and phosphorylation by cyclin/Cdk complexes
and is required for efficient HPV replication in vivo (Ma et al.,
1999). The ATP-binding site (GPPDTGKS) of an ATP-
dependent helicase is also conserved.
CfPV-2 E2 has a predicted transactivating domain within its
amino-terminal half and a DNA-binding and dimerization
domain located in the carboxyl-terminal region. The known E2
proteins bind the consensus sequence, ACCN6GGT (Androphyet al., 1987), and regulate transcription from promoters
containing E2-binding sequence (Haugen et al., 1988). CfPV-
2 has three E2-binding sites within the upstream regulatory
region (URR) sequence. There are also three polyadenylation
sites (AATAAA) in the upstream URR and a TATA box in the
downstream URR.
The CfPV-2 E4 ORF is 933 bps and overlaps the E2 region,
but in a different reading frame. The E4 gene exhibits low
sequence homology to the E4 genes of other papillomaviruses,
although it does have a characteristic high proline content (more
than 15%).
CfPV-2 encodes a 41 amino acid E5 protein which is
missing in COPV. This protein is a highly hydrophobic protein
with an average hydropathicity (GRAVY) index of 1.985 and
Ile+Leu+Val content of 48.8%. It has a putative transmem-
brane domain between amino acids 10–32. The CfPV-2 E5
protein does not share a high level of amino acid homology
with other E5 proteins, including those from BPV-1 or HPV-16
(Table 2). Interestingly, the CfPV-2 E5 protein is not closely
related to any of the four proposed E5 groups (Bravo and
Alonso, 2004), although it does resemble the BPV-1 E5 protein
in size, the presence of C-terminal cysteine residues and the
existence of polar residues in the transmembrane domain.
The DNA sequence and organization of the L1 and L2
proteins of CfPV-2 are similar to other papillomavirus capsid
proteins. Translocation of the papillomavirus L1 and L2
proteins to the nucleus is mediated by nuclear localization
signals (NLS) containing a high proportion of positively
charged residues (K and R). CfPV-2 L1 contains a bipartite
NLS, KRPATAKRAPTSKKRRK, at its carboxyl-terminus. The
highest L1 sequence homology was observed with BPV-6
(59%) and HPV-4 (58%). The L2 protein contains two NLS
domains, one at the N-terminus and one at the C-terminus.
Otherwise, the L2 protein sequence homology between CfPV-2
and other papillomaviruses was low.
CfPV-2 does not induce oral warts
It is clear from clinical cases that CfPV-2 induces papillomas
on the footpad whereas COPV seems to be selective for oral and
genital mucosa. However, to further verify these apparent
differences in tropism, we challenged the oral mucosa of dogs
with both viral types. We could not challenge dogs at the
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are painful and debilitating. Four dogs were divided into 2
groups, and each group was challenged on the oral mucosa with
either purified COPVor purified CfPV-2. Dogs were evaluated
weekly for 14 weeks after challenge for the appearance and size
of oral papillomas. Four weeks after viral challenge, the COPV
group developed typical oral papillomas (Fig. 4A). The group
challenged with CfPV-2 remained free of papillomas for at least
14 weeks. It appears, therefore, that CfPV-2 cannot induce
tumors in the oral mucosa of immunocompetent dogs.
CfPV-2 induces type-specific antibodies
Our sequencing data suggest that the capsid proteins of
CfPV-2 and COPV are only distantly related. To verify this at
the immunological level, we used ELISA to screen for possible
cross-reactivity between antibodies against intact CfPV-2 and
COPV virus. COPV antiserum was already available from our
previous studies (Chen et al., 1998). CfPV-2-specific antibodies
were generated by injecting 100 μg of purified CfPV-2 virions
into a rabbit intradermally 3 times at 2 weeks intervals. The
rabbit was phlebotomized 2 weeks after the third immunization,
and the serum fraction collected. When the CfPV-2 antiserum
was tested in ELISA, it demonstrated strong reactivity againstFig. 4. COPVand CfPV-2: tissue tropism and type-specific antigenicity. (A) COPVa
abraded and infected with either COPV or CfPV-2 as described. At 4 weeks, tumor
infected animals. Animals were observed for an additional 2 months until COPV tum
still tumor-free. (B) COPVand CfPV-2 virions induce type-specific antibodies. Rabbit
Materials and methods and the reactivity of the antisera with purified virions was tes
vice versa.CfPV-2 virus but only background reactivity against COPV
(Fig. 4B). Similarly, antiserum against COPV virus reacted
strongly with COPV but not significantly with CfPV-2. It
appears, therefore, that these antisera are type-specific and that
CfPV-2 and COPV induce distinct, non-cross-reactive anti-
bodies. It is presumed, therefore, that previous infection with
COPV will not protect dogs against CfPV-2 infection, which is
consistent with our clinical data.
Discussion
Papillomas have been observed clinically at multiple ana-
tomic sites on the dog, including the mucosa of the oral cavity
and conjunctiva as well as the epithelium of the penis, vulva,
and epidermis (Nicholls and Stanley, 1999). Studies suggest an
etiologic role for a canine papillomavirus in the induction of
cutaneous squamous papillomas (Campbell et al., 1988),
cutaneous inverted papillomas (Shimada et al., 1993) and
pigmented epidermal nevus (Tanabe et al., 2000). It has been
postulated that there is more than one type of canine
papillomavirus responsible for these neoplastic lesions. To
date, however, only COPV has been completely cloned,
sequenced and characterized (Sundberg et al., 1994). The L1
region of a canine papillomavirus causing pigmented epidermalnd CfPV-2 differ in their ability to induce oral papillomas. Dog oral mucosa was
s were observed in the COPV-infected animals (arrow) but not in the CfPV-2-
ors had completely regressed, at which time the CfPV-2 challenged animals were
antisera were generated against purified COPVor CfPV-2 virions as described in
ted by ELISA. COPV-induced antibodies reacted preferentially with COPVand
34 H. Yuan et al. / Virology 359 (2007) 28–36nevus has been partially sequenced (Tanabe et al., 2000), and it
is more related to HPV than COPV or CfPV-2.
COPV induces benign mucosal papillomas in the oral cavity
of young dogs. The lesions have a typical exophytic phenotype,
and usually spontaneously regress within 4 to 8 weeks. In
contrast, cutaneous papillomas caused by CfPV-2 occur un-
commonly in the dog, have an endophytic phenotype and take a
longer time to regress. Cutaneous papillomas have been seen
primarily in dogs during immununosuppression. Recently,
CfPV-2 has also been identified in cutaneous papillomas from
X-linked severe combined immunodeficiency (XSCID) dogs
that had been transplanted with hematopoietic stem cells
(Goldschmidt et al., 2006). Although these hematopoietic
stem cell transplanted dogs reconstitute normal T cell function
as well as normal humoral immune function, they are
susceptible to infection by CfPV-2. Most significant, however,
is the observation that persistent CfPV-2 infection in these dogs
leads to the progression of papillomas into invasive, metastatic
squamous cell carcinoma. The distant metastasis of epidermal
squamous cell carcinomas in dogs is extremely unusual.
Papillomaviruses are known to have a high degree of host
and tissue specificity and our studies indicate that this applies to
COPV and CfPV-2 as well. CfPV-2 cannot induce tumors on
the oral mucosa of immunocompetent animals. In addition,
these two viruses induce type-specific antibodies that do not
cross-react.
Unlike COPV, CfPV-2 has an E5 ORF. The E5 protein of
BPV-1 is a strong oncoprotein (reviewed in DiMaio and
Mattoon, 2001; Suprynowicz et al., 2006) and may have a role
in the initiation and maintenance of benign tumors in vivo. In
HPV, the in vivo role of the E5 protein is less well defined, but
recent studies have shown that the high-risk HPV-16 E5
protein induces rapid tumor formation and progression to
cancer in transgenic mice (Genther Williams et al., 2005).
Using the CfPV-2 model, it should now be possible to directly
examine the role of E5 in vivo and in the context of the intact
virus.
The oncogenic activities of high-risk HPV E6 and E7 have
been documented extensively (reviewed in Mantovani and
Banks, 2001; Munger et al., 2001). Like high-risk HPVs, the
CfPV-2 E6 protein contains a carboxyl-terminal PDZ ligand
motif. PDZ domain proteins play a major role in many cellular
signal transduction pathways (van Ham and Hendriks, 2003)
and studies with a transgenic mouse model demonstrate that the
PDZ ligand domain on E6 is required for transformation
(Nguyen et al., 2003). In contrast to high-risk HPV E7, CfPV-2
E7 does not contain an Rb-binding motif. Since the ability of the
HPV E7 proteins to bind and degrade RB is closely coupled
with malignant potential and cell transformation (Munger et al.,
2001), it is unclear at this time how CfPV-2 induces tumors that
progress to cancer. It will be important in the future to analyze
the ability of the CfPV-2 protein to functionally interact with the
Rb pathway.
Our phylogenetic analysis indicates that CfPV-2 is distantly
related to COPV as well as all other papillomaviruses (Fig. 4).
The highest L1 sequence similarity was found with BPV-6 and
HPV-4 (59% and 58%, respectively). This dissimilar sequencehomology, therefore, places CfPV-2 in a novel papillomavirus
genus. From a biological standpoint, the striking difference in
genetic and biological properties between COPV and CfPV-2
makes possible new inquiries into type-specific host immune
responses, tissue tropism and the comparative analysis of viral
gene functions.
Materials and methods
DNA isolation and sequencing
CfPV-2 genomic DNA was isolated from a footpad
papilloma by alkaline lysis and purified by cesium gradient
centrifugation (Delius et al., 1994). The genome was digested
with digested with BglII and subcloned into a modified pBR322
vector. In addition, viral DNAwas also extracted from purified
virions, digested with SacI and subsequently cloned into a
modified pBR322 vector. Sequencing was performed by
fluorescent sequencing in an ABI model 377 sequencer. The
sequences from both sources are identical. The nucleotide and
cDNA sequence data reported in this paper were submitted in
GenBank using the BankIt submission tool (NCBI, Bethesda,
MD) with accession number AY722648.
Viral propagation
CfPV-2 virus was propagated using a mouse xenograft
system (Bonnez et al., 1993). In brief, fresh dog buccal mucosa
was incubated with wart homogenate for 2 h, and then
implanted under the renal capsule of three SCID mice. Ten
weeks later, the mice were sacrificed and the grafts were
collected. The tissue was cut into small pieces and homogenized
in extraction buffer (0.02 M Tris, pH 7.5, 1.0 M NaCl, 30 μM
PMSF) using a Dounce homogenizer. The homogenate was
centrifuged at 10,000 rpm for 30 min at 4 °C using an HB-4
rotor (Sorvall centrifuge). The supernatant (about 3 ml) was
transferred to a Ti centrifugation tube and ultracentrifuged at
4 °C, 35,000 rpm for 101 min (70 Ti rotor). The pellet was
resuspended in a total of 20 ml of CsCl (D=1.333) using a
Dounce homogenizer. The CsCl solution (5 ml each tube) was
then centrifuged at 30,000 rpm for 20 h (55 Ti rotor) at 4 °C.
The band containing virions was aspirated from the side of the
centrifuge tube with a 3 ml syringe (23 gauge needle) and
dialyzed against phosphate-buffered saline containing phenyl-
methylsulfonylfluoride (overnight at 4 °C).
Electron microscopy of viral particles
The purified COPV and CfPV-2 viruses were adsorbed to
glow-discharged, carbon-coated grids (EM Sciences, Fort
Washington, PA) and stained with 2% uranyl acetate. A JEOL
100-CX electron microscope was used for visualization.
Immunohistochemical staining
Formalin-fixed, paraffin-embedded tissue was used for
histology (hematoxylin and eosin) and immunohistochemical
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hydrated with ethanol. Endogenous peroxidase was blocked
with 3% hydrogen peroxide. The slides were first incubated
with rabbit anti-bovine papillomavirus antibodies (dilution
1:1000, B508, Dako, Carpinteria, CA) at 4 °C for 18 h. The
slides were then incubated with biotinylated secondary antibody
(1:1000, DAKO) in a humid chamber at 37 °C for 30 min,
followed by incubation with streptavidin–biotin–peroxidase
complex (StreptABC kit, DAKO). The chromogenic substrate
was 60% diaminobenzidine in phosphate-buffered saline, and
hematoxylin was used for counterstaining.
Immunoblot analysis of viral capsid protein expression
Proteins were separated in 4–20% gradient SDS-PAGE gels
and then electrophoretically transferred to a polyvinylidenedi-
fluoride membrane. The primary antibody, a mouse anti-AU1
monoclonal antibody, was used at 1:1000 dilution. The
secondary antibodies, alkaline phosphatase-conjugated goat
anti-mouse and anti-rabbit antibodies (Tropix, Bedford, MA),
were also used at 1:1000 dilution. Immunoblots were developed
using the CDP-Star chemiluminescent substrate (Tropix).
DNA and protein sequence analysis
The putative open reading frames of CfPV-2 were identified
with ORF Finder (http://www.ncbi.nlm.nih.gov/gorf/gorf.html).
Pairwise sequence alignments were calculated using the Needle
program of EMBOSS Pairwise Alignment Algorithms (http://
www.ebi.ac.uk/emboss/align/) at European Bioinformatics
Institute (EBI) of European Molecular Biology Laboratory
(EMBL). Multiple sequence alignments of L1 were prepared
using Clustal W. Phyllogenetic analysis was conducted using
the Mega version3.0 (Kumar and Nei, 2004).
Viral challenge of dogs
Four beagles (Marshall Farm, North Rose, N.Y.) were
randomly distributed into two groups. Groups A and B were
challenged with COPVand CfPV-2 respectively as described in
earlier studies (Yuan et al., 2001). Briefly, the maxillary buccal
mucosa of the dogs was abraded with a sterile wire brush and
wart homogenate applied to the excoriated mucosa with a cotton
swab. All animal experiments were approved by theGeorgetown
University Animal Care and Use Committee, and the procedures
are consistent with Public Health Service guidelines (20).
Enzyme-linked immunosorbent assays (ELISA)
Ninety-six well plastic plates (Dynex Immulon 2 HB,
Chantilly, Virginia) were coated with purified CfPV-2 virions
(0.1 ng per well) and incubated at 37 °C for 1 h, washed with
phosphate-buffered saline (PBS) and then blocked with 1%
bovine serum albumin at 37 °C for 1 h. The dog serum (1:50
dilution with PBS) was added to the wells, incubated with
antigen at 37 °C for 1 h, and washed with PBST (PBS plus
0.05% Tween). Horseradish peroxidase-conjugated sheep anti-dog IgG antibody (Bethyl, Montgomery, TX) was then added to
the wells reacted with anti-CfPV-2 antiserum. After washing
with PBST, peroxidase substrate (KPL, Gaithersburg, MD) was
added. The reaction was terminated by the addition of stop
solution (KPL) within 10 min and absorbancy at 450 nm was
measured with a Dynatech Micro ELISA reader.
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